Genetic Engineering and Biotechnology News Jan. 15, 2013 GEN News Highlights.
Velocity Pharmaceutical Development (VPD) will use a special-purpose virtual development company to carry out research and development of new peptide drugs.
VPD’s development team will manage the development program, which will use EuMederis Pharmaceuticals’ EuPort™ technology for improving the design, synthesis, and delivery of peptides. EuPort™ uses a chemical modification to increase the duration of action and bioavailability of peptides, generating what the company called optimized new chemical entities. The technology is designed to help develop the drugs quickly as well as counteract the short duration of action and self-injection requirements of typical peptide drugs, which limit their utility.
